Pumpless and Anticoagulation-Free Extracorporeal Membrane Oxygenation
Abstract
Our ultimate objective is to create the silicon membrane (SM)-based blood oxygenator enabling wider use of extracorporeal membrane oxygenation (ECMO) for coronavirus disease of 2019 (COVID-19) patients with acute respiratory distress syndrome (ARDS). Furthermore, the SM blood oxygenator will treat patients presenting with ARDS due to other etiologies. This project addresses the Respiratory Health Topic Area. As of May 7, 2021, there were over 150 million confirmed cases of COVID-19 worldwide and over 30 million cases in the U.S. COVID-19 causes ARDS, which is a life-threatening complication. ARDS is most often treated by mechanical ventilation but results in extremely poor survival. In contrast, ECMO has demonstrated superior outcomes in comparison to mechanical ventilation. Two studies have shown a significant reduction in mortality when ARDS patients are treated by ECMO instead of mechanical ventilation. Consequently, the widespread use of ECMO will improve the survival of COVID-19 patients with ARDS. Unfortunately, ECMO use is severely limited by its complexity and associated complications due to the ECMO circuit’s non-ideal blood compatibility requiring high doses of anticoagulation, resulting in serious clotting and bleeding risks. The SM blood oxygenator will improve the biocompatibility of the ECMO circuit and therefore reduce both the complexity and the risks. The SM blood oxygenator will not require continuous and labor-intensive monitoring. Ultimately, the SM blood oxygenator will enable wider use of ECMO for COVID-19 patients with ARDS. Furthermore, the SM blood oxygenator will treat patients presenting with ARDS due to other etiologies.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Dec 28, 2022
- Source ID
- W81XWH2210149
Entities
People
- Shuvo Roy
Organizations
- United States Army
- University of California, San Francisco